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Background: Succinate dehydrogenase subunit B (SDHB) mutations are associated with aggressive
pheochromocytoma (PHEO)/paraganglioma (PGL) behavior, often resulting in metastatic disease and fatal
outcomes. These tumors are often larger, extra-adrenal, and contain lower catecholamine concentrations than other
hereditary PHEOs/PGLs. This study evaluated the size and age at diagnosis of primary SDHB-related PHEOs/PGLs as
independent predictors of their metastatic behavior and outcome (survival).
Methods: One hundred six patients with SDHB mutation-related PHEO/PGL were included in this retrospective
study. The recorded largest diameters, locations, and patient ages at initial diagnosis of SDHB-related primary tumors
were analyzed in the context of time to metastasis and patient survival.
Results: First, the development of metastatic disease in patients with primary tumors ≥4.5 cm was significantly
earlier than in patients with smaller tumors (P = 0.003). Second, patients with primary tumors larger than 5.5 cm also
had worse overall survival than patients with smaller tumors (P = 0.008). Third, age at initial diagnosis was found to
be an independent predictor of patient survival (PHEOs: P = 0.041; PGLs: P < 0.001). Fourth, we did not observe a
significant difference in survival based on the specific SDHB mutations or patient sex.
Conclusion: Receiver operating characteristic curves established 4.5 cm as the best value to dichotomize the
primary SDHB-related PHEO/PGL in order to evaluate the development of metastatic disease and 5.5 cm as the best
value for survival prediction. Subsequently, the size of the primary tumor was found as an age-independent
predictor of patient survival and metastases development in PGL. In both PHEO and PGL, age at diagnosis was
found to be a size-independent predictor of patient survival. No significant difference was found in metastases
development or patient survival between males and females or among specific SDHB mutations. This data further
extends and supports previous recommendations that carriers with SDHB mutations must undergo early and regular
evaluations to detect PHEO/PGL in order to achieve the best clinical outcome.
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According to the 2004 WHO classification of tumors,
pheochromocytomas (PHEOs) arise from chromaffin
cells of neural crest origin in the adrenal medulla. Closely
related paragangliomas (PGLs) arise from cells of sympa-
thetic or parasympathetic paraganglia [1]. These tumors
synthesize catecholamines that are metabolized to meta-
nephrines, which are preferentially used in the biochem-
ical diagnosis of these tumors [2].
Mutations in succinate dehydrogenase subunit B
(SDHB), first described by the pioneering work of Astuti
et al. in 2001 [3], have been linked to more aggressive
tumor behavior, presenting with a higher metastatic rate
than other PHEOs/PGLs [3-7]. The rate of metastasis of
SDHB-related PHEOs/PGLs has been reported to be be-
tween 34% [8] and 71% [9], with a 5-year survival rate of
36% after the diagnosis of metastasis [5]. Other SDHx
mutations have approximate metastatic rates as follows:
SDHA, 0-14%; SDHC, rarely malignant; SDHD, <5% [10].
In addition, regardless of SDHB mutation status, tumor
size has also been shown to be related to developing meta-
static disease [11]. Recently, Eisenhofer and colleagues
have described an increase in the likelihood of metastases
in PHEOs from less than 6% for tumors smaller than 5 cm
to over 50% in tumors larger than 10 cm; for PGLs, the
rate of malignancy increases to over 80% for tumors larger
than 9 cm. However, in their study, the genetic back-
ground was not considered [12].
While SDHB mutations are considered powerful pre-
dictors of malignancy, it is unclear why SDHB-related
PHEOs/PGLs in particular are more aggressive, often
metastatic, and ultimately fatal, even though some other
hereditary PHEOs/PGLs are also pseudohypoxic and
belong to the same Cluster I [13,14]. Some unique in-
sights into the presentation and pathogenesis of these
tumors have been published recently by Eisenhofer
et al. [12,15], Loriot et al. [16], and Amar et al. [5,9].
These studies either confirmed or first showed that
SDHB-related PHEOs/PGLs are most commonly extra-
adrenal and larger at first presentation, with a charac-
teristic noradrenergic and/or dopaminergic biochemical
phenotype, as well as much lower catecholamine tumor
concentrations than any other sporadic or hereditary
PHEOs/PGLs. As a result of this lower catecholamine
content, SDHB patients may initially present with only
mild clinical symptoms that do not become worrisome
until a sufficient amount of catecholamines is released,
often in cases of already large primary tumors.
Of the unique SDHB-related PHEO/PGL characteris-
tics described above, extra-adrenal location, age at initial
presentation, size of the primary tumor, and elevated
methoxytyramine levels were introduced and confirmed
as risk factors for the metastatic behavior of PHEOs/
PGLs [11,17-19]. Therefore, it has been recommendedthat patients with SDHB-related, large, or extra-adrenal
PHEOs/PGLs should have more frequent and lifelong
follow-up [20].
In the present study, we initially used receiver operat-
ing characteristic (ROC) curves to establish cut-off sizes
for evaluation of the development of metastases and pa-
tient survival. We hypothesized that even in the presence
of an SDHB mutation, smaller tumors would have a statis-
tically significantly lower metastatic potential and longer
patient survival than larger tumors. Subsequently we cre-
ated Cox regression models aiming to establish whether
those parameters could also be considered as independent
predictors of PHEO/PGL metastatic behavior and patient
outcome. The effect of having a specific SDHB gene muta-
tion, adrenal or extra-adrenal tumor location, and their
occurrence in males or females were also analyzed statisti-
cally. Finally, survival and metastatic potential parameters,
including the presence of synchronous and metachronous
metastases, were evaluated for both 5-year and overall
survival.
Methods
We performed a single center retrospective study, evaluat-
ing only patients with SDHB-related PHEOs/PGLs seen
for evaluation or treatment at the National Institutes of
Health (NIH), a referral center for these tumors. Imaging,
surgical, and pathological study reports were carefully
reviewed in order to collect the most accurate information
about the patients. The follow-up data and information
were collected based on patients’ regular follow-up visits
at NIH or from patients’ relatives who reported their
death. All patients provided written informed consent.
The study was conducted at the NIH under Institutional
Review Board (IRB)-approved protocol 00-CH-0093.
Metastases were confirmed either by surgery or by
anatomical and PHEO/PGL-specific functional imaging
studies. When there was evidence of lesions in areas
where chromaffin cells are not present, these lesions were
considered metastatic. For the purposes of the present
study, when the metastases were observed together with a
recurrent tumor, the tumor was marked as metastatic; re-
currences were not evaluated. We use the term synchron-
ous metastases to describe the occurrence of metastases
discovered at initial diagnosis or within 6 months after the
primary tumor diagnosis. Its complementary group, pa-
tients without synchronous metastases, was divided into
those developing metastases after 6 months and those
who did not develop any detectable metastases during the
data collection period. The metastases developing after
6 months from initial diagnosis are characterized as meta-
chronous [19]. The time to metastasis parameter is the
interval between the initial diagnosis and the diagnosis of
metastatic disease (defined as 0 for those with synchron-
ous metastases).
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tumor for the development of metastases, we used the
largest diameter size of 4.5 cm as a cutoff point, the op-
timal value (which maximized the sum of the sensitivity
and specificity) based on ROC analysis; using this cutoff,
the Area Under the Curve (AUC) = 0.782, sensitivity =
80.5%, specificity = 69%. For survival analysis, we dichot-
omized the patient cohort using the largest diameter size
of 5.5 cm, the optimal cutoff point from ROC analysis
for this endpoint (AUC = 0.663, sensitivity = 87.0%, spe-
cificity = 49.5%). This value divided the patients almost
equally (Additional file 1: Figure S1). Alternatively, for
some analyses the patients were divided into four nearly
equal-sized groups according to the size of the primary
tumor (≤4 cm, 4–6 cm, 6–9 cm, >9 cm). Analyses of the
effects of various parameters on the time to metastases
and for survival used Kaplan-Meier curves to graphically
represent the results, with group comparisons based on
the standard logrank test (to compare 2 groups), the
trend version of it (to compare more than 2 groups that
are ordered), or stratified versions of these (to adjust for
a second parameter, such as PGL vs. PHEO). Survival
analyses were reported either for total survival or for sur-
vival truncated at 5 years (i.e. anyone whose observation
time was longer than 5 years was considered censored at
5 years); the same applied for “survival” analyses of time to
metastases.
To analyze the mutual effects of age at diagnosis and
the size of the primary tumor on survival, we used Cox
regression models, with 5 ordered categories for age (de-
fined by cutpoints at 20, 30, 40, 50 years old) and the
aforementioned 4 ordered categories for size. Cox regres-
sion was also used to estimate the relative hazard rates for
the 4 ordered size categories. For an alternative nonpara-
metric, model-free estimate of the probability of death or
metastases vs. tumor size, observations were divided into
bins and the lowess smoother was applied to the propor-
tions of outcomes in the bins. All survival results used
death due to disease as the endpoint. All P-values were
two-sided.
Results
Patient and tumor characteristics
One hundred six patients (39 females, 67 males) with
SDHB-related PHEOs/PGLs from the Eunice Kennedy
Shriver National Institute of Child Health & Human
Development, NIH PHEO/PGL registry were included
in the present study. The number of males in the
present study was significantly higher than the number
of females (P = 0.008), but these two groups did not
differ in any of these following parameters: size of the
primary tumor (P = 0.13); percentage of patients with
synchronous metastases (P = 0.36); time to metastasis
(P = 0.94); or overall survival (P = 0.36) (Figure 1A).Eighty-nine patients presented with PGL and 17 with
PHEO (P < 0.001). The median ages at initial diagnosis
of PGL or PHEO were 29 and 31 years, respectively. The
age at diagnosis did not differ for different tumor sizes
(Table 1). However, tumors with a smaller diameter were
diagnosed significantly more often in the recent years
(P = 0.043) (Table 1). The median size of all primary
tumors was 6 cm. The median sizes of the primary PGLs
and PHEOs were 6 cm and 8 cm, respectively (P = 0.023).
Despite differences in the median sizes of the primary
PGLs and PHEOs, the survival of patients diagnosed
with either PGL or PHEO was not significantly different
(P = 0.099) (Figure 1B). All the patients considered sur-
vival failures died due to metastatic PHEO/PGL.
Development of metastatic disease
Seventy-seven out of our 106 patients (72.6%) were diag-
nosed with metastatic disease over the course of their dis-
ease in the present study. Twenty-eight patients (26.4%)
developed metastatic disease at the time of their primary
tumor diagnosis or within six months (synchronous me-
tastases); their median age at the initial diagnosis was
31.5 years; the median size of their primary tumor was
7.5 cm. Of the 78 patients not presenting with synchron-
ous metastases, 49 (46.2% of total) went on to develop
metachronous metastases, within the median time to me-
tastases of 5 years; their median age at the initial diagnosis
was 30 years; their median size of their primary tumors
was 7.0 cm. For the remaining 29 (27.4% of total) patients
who never developed metastatic disease, the median age
at initial diagnosis was 29 years; their median size of the
primary tumor was only 3.8 cm. The size of the primary
tumors was found to be highly statistically different among
the 3 groups described above (ANOVA, P < 0.001).
Patients with SDHB-related PHEO or PGL did not differ
in the time to the development of metastasis (P = 0.54),
and the probability of a 5-year metastasis-free interval
among those without synchronous metastasis was similar
(48.2% for PGL and 55.0% for PHEO).
As described in Material and Methods, we used an ROC
curve to establish an optimal cut-off size of the primary
tumor in regards to the development of any metastases;
the primary tumor size of 4.5 cm was the size that maxi-
mized the sum of the sensitivity and specificity to develop
metastatic disease. The patients with primary tumors
<4.5 cm had a median time to develop metachronous me-
tastases of 8 years (CI 95%, 3 years to infinity), while those
with larger tumors (≥4.5 cm) had a median time of only
2 years (CI 95%, 1 to 4 years; P = 0.003) (Figure 1C).
Effect of metastatic disease development on the
survival rate
Regardless of the presence of PHEO or PGL or their
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Figure 1 Plots of survival and time to metastases were constructed based on patient characteristics. Patients were separated based on
gender (Panel A), tumor type (Panel B), primary tumor size (Panel C), and linearly increasing primary tumor size (Panel D).
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95%; 63%-84%). The 5-year survival probability from
the initial diagnosis for patients who presented with
synchronous metastases was 74.5%; for patients not
presenting with synchronous metastases, it was 96.4%
(P = 0.006). However, once the patient was diagnosed
with metastatic disease, there was no significant differ-
ence in their 5-year survival from the time of that diag-
nosis (74.5% for patients with synchronous metastases
and 77.0% for metachronous metastases; P = 0.42).As shown in Table 2, the presence of synchronous me-
tastases did not have a significant effect on the survival
of patients with the smaller tumors <5.5 cm (P = 0.63),
but it had a highly significant effect on the survival of
patients with larger tumors ≥5.5 cm (P = 0.0003). Specif-
ically, the patients with the larger tumors (≥5.5 cm) and
synchronous metastases had a 5-year survival probability
of 65.8%, while patients with the same size primary tu-
mors, but without synchronous metastases, had a 5-year
survival probability of 97.1%. Interestingly, the above
Table 1 Comparison of the 4 tumor size groups
Type of
tumor
Size of primary tumor P-value
<= 4 cm 4 - 6 cm 6 - 9 cm > 9 cm
No. of patients by tumor size group [%] ALL 32 [30] 24 [23] 25 [24] 25 [24] 0.034 (PGL vs. PHEO)
PGL 31 [35] 19 [21] 20 [22] 19 [21]
PHEO 1 [6] 5 [29] 5 [29] 6 [35]
Probability of 5-year survival [%] ALL 94.1 95 83.4 88 0.16
PGL 93.8 93.8 85.0 89.5 0.26
PHEO 100 100 75.0 83.3 0.39
Years to death(median) ALL >55 >25 12 20 0.035
PGL >55 >25 12 20 0.030
PHEO >5 9 8 17 0.58
Survival Hazard Ratio ALL 1 4.6 12.21 5.82
No. of deceased patients [%] ALL 1 [3.13] 6 [25] 10 [40] 6 [24]
Median age at diagnosis ALL 32 25 30 31 0.44
Median year of diagnosis ALL 2007 2003 2004 2003 0.043
Years to metastases (median) ALL 8 4 3 1 0.0008
Probability of 5-year “metastases-free interval” [%] ALL 66.2 34.6 25.1 19.2 0.0002
Probability of 10-year “metastases-free interval” [%] ALL 34.0 12.4 16.8 19.2 0.004
Schovanek et al. BMC Cancer 2014, 14:523 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/523findings were observed only in PGLs, not in PHEOs
(Table 2).
Effect of primary tumor size on survival time
As mentioned previously, the primary tumor cut-off size
for predicting development of metastases was 4.5 cm.
We observed that all the patients who died due to dis-
ease suffered from metastatic PHEO/PGL spread. InTable 2 5-year survival probability of patients with tumors by
presence of synchronous metastasis
Without synchronous metastases (n = 78
All tumors by type
PGL (n = 89) 97.9% (n = 66)
PHEO (n = 17) 88.9% (n = 12)
5-year/overall survival p-value 0.19/0.012
All tumors by size
<5.5 cm (n = 44) 95.2% (n = 37)
> = 5.5 cm (n = 62) 97.1% (n = 41)
5-year/overall survival p-value 0.71/0.18
PGLs by size
<5.5 cm (n = 41) 94.7% (n = 34)
> = 5.5 cm (n = 48) 100% (n = 32)
5-year/overall survival p-value 0.22/0.57
PHEOs by size
<5.5 cm (n = 3) 100% (n = 3)
> = 5.5 cm (n = 14) 85.7% (n = 9)
5-year/overall survival p-value 0.59/0.38order to provide the most precise and clinically relevant
information regarding the outcome (survival time) of
these patients, another ROC analysis was performed,
which established a 5.5 cm diameter as the optimal cut-
off size for predicting survival within the present cohort.
Accordingly, for survival analyses, patients were divided
into two groups: <5.5 cm and ≥5.5 cm. When we ana-
lyzed the effect of primary tumor size on the survivaltumor type (PHEO vs. PGL) and tumor size based on the
) Synchronous metastases (n = 28) 5-year/overall survival p-value
73.2% (n = 23) 0.0002/0.001
80.0% (n = 5) 0.56/0.94
0.79/0.89 —
100% (n = 7) 0.63/0.41
65.8% (n = 21) 0.0003/0.0028
0.09/0.021 —
100% (n = 7) 0.61/0.40
60.9% (n = 16) 0.0001/0.0002
0.068/0.014 —
N/A N/A
80.0% (n = 5) 0.68/0.86
N/A —
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with primary tumors <5.5 cm had significantly longer
overall survival than patients with ≥5.5 tumors (P = 0.008)
(Figure 1C). When the two tumor types were analyzed
separately, the effect of size was highly significant in
PGLs (P = 0.012), but was not significant in PHEOs (P =
0.39). However, this size-based survival difference in
PGLs was present only for overall survival; for survival
during the initial 5-year interval the difference between
patients with smaller and larger tumors was not signifi-
cant (P = 0.12).Effect of SDHB mutation type
In the present study, patients had a variety of SDHB mu-
tation types: 13 had deletions (PGLs 11/PHEOs 2), 7 had
frame-shift mutations (PGLs 4/PHEOs 3), 41 had mis-
sense mutations (PGLs 33/PHEOs 8), 24 had nonsense
mutations (PGLs 20/PHEOs 4), and 21 had splice site
mutations (PGLs 17/PHEOs 4). We did not find any sig-
nificant differences in tumor size or survival time among
different SDHB mutation types (P = 0.74 for size, P = 0.61
for survival time). The smallest tumors were found in the
group of patients with frame-shift mutations, the largest
tumors in patients with nonsense mutations.Size and age as independent predictors of survival and
metastatic disease
Cox regression models, including interaction terms (as
described in the Methods section), were used to evaluate
tumor size and patient age at primary diagnosis as separ-
ate survival predictors. In none of the analyses was the
interaction term between these two factors significant
and hence it was not included in the final analyses. In the
PGL group the size of the primary tumor and the age at
initial diagnosis were found to be strong independent
predictors of patient survival (P = 0.007 and P < 0.001,
respectively). In the PGL group, patients diagnosed at a
younger age had better performance, as did patients
with smaller tumors, defined by the ordered categories
as described in the Methods section. Furthermore, in
the PGL group age at diagnosis did not predict the time
to development of metastases (P = 0.51), but the size of
the primary tumor did (P = 0.003), with patients having
larger tumors more likely to develop metastatic disease.
In the PHEO group age at diagnosis was an independ-
ent predictor of patient survival (P = 0.041) but not for
the development of metastases (P = 0.21), similar to the
situation in the PGL group. In PHEO, as for PGL, younger
patients had the better performance. However, unlike
the situation in PGL patients, in PHEO tumor size was
not found to be an independent predictor of either patient
survival (P = 0.49) or the development of metastases
(P = 0.65).Discussion
In the present study of 106 patients with pathogenic
SDHB germline mutations, we found that the size of the
primary tumor is an age-independent predictor of patient
survival and metastases development in PGL. In both
PHEO and PGL, age at diagnosis was found to be a size-
independent predictor of patient survival. Furthermore,
the development of synchronous metastases significantly
affected 5-year and overall survival in patients with PGL.
Patients with PHEO had possibly worse, though it did not
reach statistical significance, overall survival than those
with PGL (P = 0.099); their survival was not affected by
the size of the primary tumor or by synchronous metasta-
ses. We did not find a significant difference in metastases
development or patient survival between males and
females or among specific SDHB mutations.
The importance of the primary tumor size for patient
prognosis in general oncology is well established, as
manifested by the use of the TNM classification [21].
Thus, previous studies have already agreed that the size
of the primary tumor is an important predictor for pa-
tient survival and for the metastatic potential of PHEO/
PGL, but none of these studies examined whether this
finding was true of tumors with specific genetic back-
grounds [12,17,19]. This study extends this knowledge,
due to its unique design, to SDHB-related PHEO/PGL.
Evaluating two different parameters (survival and time
to metastases) using ROC, we determined 2 optimal
tumor size cut-offs for our study in order to provide
more precise and clinically relevant information about
these aggressive tumors. We established the optimal pri-
mary tumor size cut-off for the development of metasta-
ses as 4.5 cm; patients with smaller tumors developed
metastases significantly later than patients with larger
tumors. For the survival analyses, the patient cohort was
separated into two groups, smaller tumors (<5.5 cm) and
larger ones (≥5.5 cm), using a cut-point that was close to
the median tumor size of PGLs, by far the larger of the
two disease groups. Patients with smaller tumors had
significantly better survival than patients with larger
tumors, without separating PGL/PHEO. These two dif-
ferent cut-offs clinically show how the development of
metastatic disease precedes disease mortality.
Alternatively the patients were divided into four groups
according to the size of the primary tumor (≤4 cm, 4–
6 cm, 6–9 cm, >9 cm); this division we considered clinic-
ally relevant and also resulted in groups of almost equal
size (32/24/25/25). The percentages with synchronous
metastases in these four groups were 22%, 13%, 28%,
and 44%, respectively (trend P = 0.049, by exact test for
contingency tables with ordered columns) (Table 1).
Studies evaluating exclusively metastatic PHEO/PGL
patients have found that about one-third of these patients
harbor pathogenic SDHB mutations [4,9]; however, the
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varies dramatically [22]. In the present study we found it
to be high, with 72.6% of the patients developing metasta-
ses over the course of the study, which is similar to the
71.7% previously reported in the study by Amar et al. [9].
Consequently, the presence of an SDHB mutation was
found to be an independent predictor of PHEO/PGL
malignant behavior [5]. Typical metastatic sites of SDHB-
related PHEO/PGL include the bones, lungs, lymph nodes,
and liver; multiple metastases are also possible [5].
Furthermore, in childhood and adolescence the inci-
dence of PHEO/PGL is rare; however, when metastatic
disease is diagnosed in these age groups, these patients
have a high probability of having SDHB mutations [23].
The present study showed better performance of younger
patients and established the age at diagnosis as a survival
predictor in patients with SDHB PHEO/PGL. Improved
survival of younger patients was already reported in a
study by Amar et al., but did not reach significance as an
independent predictor [5].
The previously reported ratio between synchronous
and metachronous metastases in various PHEOs/PGLs
was almost equal (51%/49%) [19]. In our study with only
SDHB-related tumors, we observed predominantly meta-
chronous rather than synchronous metastases (64%/36%),
which could be due to the relatively long follow-up
periods for our patients. We did not find a significant
difference in the 5-year survival between patients after
the diagnosis of synchronous or metachronous metastatic
disease, which suggest that tumors with synchronous
metastases are not inherently more aggressive.
There is still disagreement on the relative survival of
patients with PHEO and PGL. A previous study, which
did not classify the tumors based on genetic background,
found overall survival to be significantly shorter in patients
with PGLs than with PHEOs [19]. A different study, which
also did not consider the genetic background of the dis-
ease and included only metastatic PHEO/PGL, reported
better survival of PGLs [24]. Our study, including only pa-
tients with SDHB-related tumors, found that patients with
PGLs had a better overall survival than patients with
PHEOs. However the difference was not statistically sig-
nificant, quite possibly due to the small number of PHEOs
as opposed to PGLs in these patients with SDHB mu-
tations (Figure 1A). While elucidating other possible
differences between SDHB-related PHEO and PGL, we
demonstrated that the size of the primary tumor for
patients with PHEOs seems to be less important for
patient survival than for PGL. We initially attributed
this to the selected cut-off (5.5 cm), which was more
representative of the size of primary PGLs (and divided
them almost evenly) and divided the PHEOs quite un-
evenly. However, when we used 8 cm as a cutoff, the
median size of PHEO primary tumors, there was againno survival difference in PHEOs between those with
small vs. large tumors (P = 0.81) Significantly larger tu-
mors in patients with PHEO than with PGL have been
reported previously [24].
Our analysis clearly shows that the size of the primary
tumor in PGLs predicts the development of metastatic
disease and also affects patient survival, while the age at
diagnosis predicts patient survival but not the develop-
ment of metastases. In contrast, in the limited number
of SDHB-mutated PHEOs, we found that the age at
diagnosis is an important factor for survival, but the size
of the primary tumor is not. The lack of an observed sig-
nificant effect of primary tumor size in PHEOs is not in
agreement with the previous observation of Zelinka et al.
[17], who evaluated a larger sample of metastatic PHEOs,
but did not focus on the genetic background of the
PHEOs included in that study, both of which could
explain this difference.
Given the status of the NIH PHEO/PGL program as a
national and international referral center, our patient
population is typically made up of clinically more severe
and complicated cases, usually due to patients with under-
lying genetic backgrounds, which could possibly lead to
some referral bias. Therefore, we were not able to establish
a similarly sized cohort of apparently sporadic patients
that would allow us to investigate whether these tumors
would behave similarly to SDHB-related PHEO/PGL and
to elucidate how exactly the presence of an SDHB muta-
tion would affect the development of metastatic disease
and patient survival when the size of the primary tumor is
considered and compared to other PHEO/PGL types.
Since the incidence of SDHB-related PHEOs is very low
compared to SDHB-related PGLs, it was very difficult to
reliably compare these two groups, and other significant
findings might become more apparent if a larger number
of PHEOs were available. Similarly, it was very difficult to
evaluate the effect of size on metastases development in
SDHB-related PHEOs, because there were only 17 such
patients and only 4 of these (23.5%) did not develop any
metastases. Of the 89 patients with PGL, 25 (28.09%) did
not develop metastases during the follow-up period of this
study. The PGL patient cohort also included patients with
head and neck PGLs, because our main goal was to fully
evaluate the SDHB patient population; however, a bigger
patient cohort separating those patients from other PGL
patients might provide further interesting results.
Conclusions
In summary, this unique study of patients with SDHB-
related PHEO/PGL showed that the age at the primary
diagnosis as well as the size of the primary tumor are
two important independent prognostic factors. We did
not find any difference based on the sex of the patient,
but we did observe certain differences between SDHB-
Schovanek et al. BMC Cancer 2014, 14:523 Page 8 of 9
http://www.biomedcentral.com/1471-2407/14/523related PGLs and PHEOs. This data strongly supports
our recommendations that all carriers with SDHB muta-
tions should undergo early and regular evaluations to
detect tumor(s) at an early stage to achieve the best
clinical outcome with regards to their survival.
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